The Emerging Roles of Endocrine Hormones in Different Arthritic Disorders

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2021 Jun 7

PMID 34093428

Citations 15

Authors

Eugenia Bertoldo

Giovanni Adami

Maurizio Rossini

Alessandro Giollo

Giovanni Orsolini

Ombretta Viapiana

Davide Gatti

Angelo Fassio

Affiliations

Soon will be listed here.

Abstract

The relationship between endocrine hormones and the spectrum of rheumatic conditions has long been discussed in the literature, focusing primarily on sexual hormones, such as estrogens, androgens, prolactin (PRL). Estrogens are indeed involved in the pathogenesis of the main inflammatory arthritis thanks to their effects on the immune system, both stimulatory and inhibitory. The PRL system has been discovered in synovial tissue of rheumatoid arthritis (RA) and psoriatic arthritis (PsA), patients and has been propose as a new potential therapeutic target. Besides sexual hormones, in the last years scientific interest about the crosstalk of immune system with other class of hormones has grown. Hormones acting on the bone tissue (i.e. parathyroid hormone, vitamin D) and modulators of the Wnt pathway (i.e. Dickkopf-1) have been demonstrated to play active role in inflammatory arthritis course, defining a new field of research named osteoimmunology. PTH, which is one of the main determinants of Dkkopf-1, plays a crucial role in bone erosions in RA and a correlation between PTH, Trabecular Bone Score (TBS) and disease activity has been found in ankylosing spondylitis (AS). In PSA is under studying the interaction among IL-17 and bone metabolism. The purpose of this review is to discuss and summarize the recent data about the interaction between endocrine hormone and immune system in the main rheumatic disorders, covering in particular the role of bone-related hormones and cytokines. We will describe this relationship from a biochemical, diagnostic and therapeutic perspective, with a particular focus on RA, PsA and AS.

Citing Articles

An Actual Insight into the Pathogenic Pathways of Ankylosing Spondylitis.

Pasaran E, Diaconu A, Oancea C, Balanescu A, Aurelian S, Homentcovschi C Curr Issues Mol Biol. 2024; 46(11):12800-12812.

PMID: 39590356 PMC: 11592934. DOI: 10.3390/cimb46110762.

Two-sample Mendelian Randomization to evaluate the causal relationship between inflammatory arthritis and female-specific cancers.

Meisinger C, Fischer S, OMara T, Freuer D J Transl Med. 2024; 22(1):962.

PMID: 39449068 PMC: 11515448. DOI: 10.1186/s12967-024-05765-9.

The Multifaceted Impact of Environmental Pollutants on Health and Ecosystems.

Piscopo M, Marinaro C, Lettieri G Biomolecules. 2024; 14(8).

PMID: 39199408 PMC: 11352651. DOI: 10.3390/biom14081021.

Unveiling the Nexus: Cellular Metabolomics Unravels the Impact of Estrogen on Nicotinamide Metabolism in Mitigating Rheumatoid Arthritis Pathogenesis.

Malik S, Chakraborty D, Agnihotri P, Kumar V, Biswas S Metabolites. 2024; 14(4).

PMID: 38668342 PMC: 11052502. DOI: 10.3390/metabo14040214.

Bone metabolism and inflammatory biomarkers in radiographic and non-radiographic axial spondyloarthritis patients: a comprehensive evaluation.

Gomez-Garcia I, Ladehesa-Pineda M, Diaz-Tocados J, Lopez-Medina C, Abalos-Aguilera M, Ruiz-Vilches D Front Endocrinol (Lausanne). 2024; 15:1227196.

PMID: 38449853 PMC: 10915870. DOI: 10.3389/fendo.2024.1227196.

References

Berglin E, Kokkonen H, Einarsdottir E, Agren A, Rantapaa Dahlqvist S . Influence of female hormonal factors, in relation to autoantibodies and genetic markers, on the development of rheumatoid arthritis in northern Sweden: a case-control study. Scand J Rheumatol. 2010; 39(6):454-60. DOI: 10.3109/03009741003742763. View

Senolt L, Hulejova H, Krystufkova O, Forejtova S, Andres Cerezo L, Gatterova J . Low circulating Dickkopf-1 and its link with severity of spinal involvement in diffuse idiopathic skeletal hyperostosis. Ann Rheum Dis. 2011; 71(1):71-4. DOI: 10.1136/annrheumdis-2011-200357. View

Simon D, Kleyer A, Bayat S, Tascilar K, Kampylafka E, Meinderink T . Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients. Arthritis Res Ther. 2019; 21(1):162. PMC: 6607518. DOI: 10.1186/s13075-019-1938-3. View

Mitra D, Elvins D, Speden D, Collins A . The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology (Oxford). 2000; 39(1):85-9. DOI: 10.1093/rheumatology/39.1.85. View

Gatti D, Viapiana O, Idolazzi L, Fracassi E, Rossini M, Adami S . The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab. 2011; 96(5):1555-9. DOI: 10.1210/jc.2010-2552. View

Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B . The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003; 349(26):2483-94. DOI: 10.1056/NEJMoa030847. View

Rossini M, Viapiana O, Adami S, Fracassi E, Idolazzi L, Dartizio C . In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. Clin Exp Rheumatol. 2014; 33(1):77-83. View

Malysheva K, de Rooij K, Lowik C, Baeten D, Rose-John S, Stoika R . Interleukin 6/Wnt interactions in rheumatoid arthritis: interleukin 6 inhibits Wnt signaling in synovial fibroblasts and osteoblasts. Croat Med J. 2016; 57(2):89-98. PMC: 4856197. DOI: 10.3325/cmj.2016.57.89. View

Zhang W, Dang K, Huai Y, Qian A . Osteoimmunology: The Regulatory Roles of T Lymphocytes in Osteoporosis. Front Endocrinol (Lausanne). 2020; 11:465. PMC: 7431602. DOI: 10.3389/fendo.2020.00465. View

10.

Zachary C, Fackler N, Juhasz M, Pham C, Atanaskova Mesinkovska N . Catamenial dermatoses associated with autoimmune, inflammatory, and systemic diseases: A systematic review. Int J Womens Dermatol. 2020; 5(5):361-367. PMC: 6938828. DOI: 10.1016/j.ijwd.2019.09.008. View

11.

Pedersen M, Jacobsen S, Klarlund M, Pedersen B, Wiik A, Wohlfahrt J . Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther. 2006; 8(4):R133. PMC: 1779386. DOI: 10.1186/ar2022. View

12.

Tsokos G . Systemic lupus erythematosus. N Engl J Med. 2011; 365(22):2110-21. DOI: 10.1056/NEJMra1100359. View

13.

Jimenez-Balderas F, Murrieta S, Mintz G . Ovarian function studies in active ankylosing spondylitis in women. Clinical response to estrogen therapy. J Rheumatol. 1990; 17(4):497-502. View

14.

El Maghraoui A . Osteoporosis and ankylosing spondylitis. Joint Bone Spine. 2004; 71(4):291-5. DOI: 10.1016/j.jbspin.2003.06.002. View

15.

Pothuaud L, Carceller P, Hans D . Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture. Bone. 2008; 42(4):775-87. DOI: 10.1016/j.bone.2007.11.018. View

16.

Jensen T, Hansen M, Jensen K, Podenphant J, Hansen T, Hyldstrup L . Comparison of dual X-ray absorptiometry (DXA), digital X-ray radiogrammetry (DXR), and conventional radiographs in the evaluation of osteoporosis and bone erosions in patients with rheumatoid arthritis. Scand J Rheumatol. 2005; 34(1):27-33. DOI: 10.1080/03009740510017986. View

17.

Thompson M, Siminovitch K, Cole D . G protein-coupled receptor pharmacogenetics. Methods Mol Biol. 2008; 448:139-85. DOI: 10.1007/978-1-59745-205-2_8. View

18.

Nguyen C, Maverakis E, Eberl M, Adamopoulos I . γδ T cells in rheumatic diseases: from fundamental mechanisms to autoimmunity. Semin Immunopathol. 2019; 41(5):595-605. PMC: 6815259. DOI: 10.1007/s00281-019-00752-5. View

19.

Viapiana O, Fracassi E, Troplini S, Idolazzi L, Rossini M, Adami S . Sclerostin and DKK1 in primary hyperparathyroidism. Calcif Tissue Int. 2013; 92(4):324-9. DOI: 10.1007/s00223-012-9665-7. View

20.

Duryea J, Gravallese E, Wortman J, Xu C, Lu B, Kay J . Healing of erosions in rheumatoid arthritis remains elusive: results with 24 months of the anabolic agent teriparatide. Scand J Rheumatol. 2020; 50(1):11-14. DOI: 10.1080/03009742.2020.1772362. View